Emerging roles and clinical perspectives of long noncoding RNAs in prostate cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Long noncoding RNAs (lncRNAs) are key regulators in prostate cancer (PCa) development and progression. Understanding lncRNA networks offers new hope for improved diagnosis and personalized treatments for PCa patients.
Area Of Science
- Oncology
- Molecular Biology
- Genetics
Background
- Prostate cancer (PCa) remains a significant global health challenge, with aggressive and treatment-resistant forms posing major hurdles.
- Long noncoding RNAs (lncRNAs) are increasingly recognized as critical regulators in PCa, influencing cell cycle, gene expression, and metastasis.
- Dysregulated lncRNAs impact crucial cellular processes and drive PCa progression, including modulating androgen receptor (AR) signaling.
Purpose Of The Study
- To review and integrate recent advances in lncRNA-mediated regulatory networks in PCa.
- To highlight the roles of lncRNAs in epigenetic, post-transcriptional regulations, and key signaling pathways.
- To underscore the clinical applications of lncRNAs as predictive biomarkers and therapeutic targets for personalized medicine.
Main Methods
- Comprehensive literature review of recent research on lncRNAs in PCa.
- Analysis of lncRNA functions in epigenetic and post-transcriptional regulation.
- Integration of data on lncRNA involvement in PCa signaling pathways and clinical relevance.
Main Results
- lncRNAs play pivotal roles in PCa pathogenesis, influencing tumor growth, progression, and metastasis.
- lncRNAs act as competitive endogenous RNAs (ceRNAs), affecting microRNA targets and gene expression.
- lncRNAs are implicated in modulating AR signaling, a critical pathway in PCa.
Conclusions
- lncRNA research offers significant promise for improving early PCa diagnosis and developing effective, personalized therapies.
- Understanding complex lncRNA networks is crucial for overcoming challenges like patient heterogeneity.
- Translating lncRNA research into clinical applications requires continued investigation into their therapeutic potential.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in regulating gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA Performs Diverse...
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...